Broad-spectrum Rapid Antidote: Varespladib IV to Oral Trial for Snakebite (BRAVIO)
Public ClinicalTrials.gov record NCT05717062. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Intravenous Varespladib Followed by Oral Varespladib in Addition to Standard of Care in Subjects Bitten by Venomous Snakes
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a multicenter,randomized,double-blind, placebo-controlled, phase 2 study designed to evaluate the safety, tolerability and efficacy of a continuous rate infusion (CRI) of IV varespladib followed by transition to the oral dosage form, varespladib-methyl, concurrently with SOC, in participants bitten by venomous snakes. Note: Funding Source - FDA-OOPD
Study identification
- NCT ID
- NCT05717062
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 140 participants
Conditions and interventions
Conditions
Interventions
- Varespladib intravenous form Drug
- varespladib-methyl- oral form Drug
- Placebo intravenous form Drug
- Placebo - oral form Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 30, 2023 (Actual)
- Primary completion
- Nov 28, 2024 (Actual)
- Completion
- Feb 24, 2025 (Actual)
- Last update posted
- Jun 27, 2025
2023 – 2025
United States locations
- U.S. sites
- 10
- U.S. states
- 6
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Banner University Medical Center - Phoenix | Phoenix | Arizona | 85006 | — |
| Arizona Poison & Drug Information Center | Tucson | Arizona | 85721 | — |
| Desert Regional Medical Center | Palm Springs | California | 92262 | — |
| Antelope Valley Medical Center | Rosamond | California | 93560 | — |
| UF Health Shands Hospital | Gainesville | Florida | 32610 | — |
| University of South Florida/Tampa General Hospital | Tampa | Florida | 33606 | — |
| Emergency Medicine, University of Kentucky | Lexington | Kentucky | 40536 | — |
| Duke University Medical Center | Durham | North Carolina | 27710 | — |
| Texas Tech University Health Sciences Center El Paso | El Paso | Texas | 79905 | — |
| UT Health San Antonio | San Antonio | Texas | 78229 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05717062, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 27, 2025 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05717062 live on ClinicalTrials.gov.